Rocket Lab’s Neutron Countdown and Iridium Bet Collide With a 54% Share Price Wipeout
Published on 07/24/2026 at 14:01 | Redaktion boerse-global.de
Rocket Lab’s stock has been cut in half since late May, yet the company is posting record revenue and signing its largest-ever launch contracts. The contradiction is testing investor patience as two transformative bets — the Neutron rocket’s debut and a $3.6 billion Iridium acquisition — converge on a single, volatile timeline.
At €61.50, shares trade 54% below the all-time high of €133.80 touched on May 27. The slide has erased all of 2026’s first-half gains, leaving the stock flat year-to-date. Over a 12-month horizon, however, the equity still shows a 50% advance — a reminder that the selloff is a correction within a longer bull run, not a collapse of the underlying business.
A Sector Rotation, Not a Business Breakdown
The primary driver of Rocket Lab’s decline has little to do with the company’s operations. The late-June IPO of SpaceX, valued at roughly $2 trillion, triggered a capital rotation across the space sector. Investors who had used Rocket Lab as a proxy for SpaceX exposure are now shifting directly into the newly public stock, creating a mechanical headwind that has nothing to do with launch failures or lost contracts.
That technical pressure was amplified by poorly timed insider sales. CEO Peter Beck executed a pre-arranged 10b5-1 trading plan between July 6 and 8, selling shares at prices between roughly $82 and $102. While the plan was established in advance, the execution window coincided with the stock’s weakest phase, adding a layer of psychological damage to an already fragile chart.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The result is a technical picture that screams oversold. The relative strength index sits at 34.7, and the stock trades roughly 32% below its 50-day moving average of €90.08. The 30-day annualized volatility has spiked to nearly 89%, reflecting the whipsaw nature of recent trading.
Record Revenue and a Growing Backlog
Operationally, Rocket Lab has never been stronger. First-quarter 2026 revenue hit $200.3 million, a 63.5% year-over-year jump that marked a company record. The backlog swelled 20% to more than $2.2 billion, fueled by 31 new launch contracts added in the quarter alone. The VICTUS-HAZE mission for the US Space Force added further validation.
In May, Rocket Lab signed the largest contract in its history: an unnamed customer ordered five Neutron and three Electron flights, spread across launch sites in New Zealand and Virginia between 2026 and 2029. The deal underscores the market’s appetite for Neutron’s medium-lift capability even before the rocket has flown.
Neutron: Progress Amid Setbacks
The centerpiece of Rocket Lab’s growth story remains Neutron, and the company is holding firm to a fourth-quarter 2026 target for the rocket’s first flight. Recent hardware milestones include a full-duration burn test of the vacuum-optimized Archimedes engine for the second stage, which delivers roughly 1.2 times the thrust of the sea-level version through a significantly longer nozzle.
But the program has not been friction-free. Earlier in the year, Rocket Lab lost components originally intended for flight hardware, a setback that contributed to earlier schedule delays. The company is now running parallel workstreams on other flight elements alongside engine development, but public disclosure on overall hardware progress has been thin since January.
That information vacuum helps explain the stock’s extreme volatility. Five firm commercial missions are already booked for Neutron before its maiden flight, yet investors have little visibility into whether the rocket will meet its year-end deadline. A clean first flight would validate years of patience; another delay would reopen the wound in the share price.
The Iridium Merger: Strategic Logic, Financial Complexity
Adding to the uncertainty is the planned acquisition of Iridium, a deal that would transform Rocket Lab from a pure-play launch provider into a vertically integrated satellite communications operator. The transaction gives Rocket Lab access to Iridium’s globally licensed L-band spectrum and a satellite network serving more than 2.5 million subscribers.
The structure is intricate. Iridium shareholders will receive $27 in cash plus Rocket Lab shares, for a combined value of $54 per Iridium share — a 24.1% premium to the pre-announcement close. Rocket Lab has secured a $3.6 billion bridge financing facility from Deutsche Bank and Wells Fargo to cover the cash component, and will supplement it with internal funds and additional debt or equity.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
The final dilution for existing Rocket Lab shareholders depends on the stock price at closing. A collar mechanism between $67.50 and $112.50 determines the exact share count issued to Iridium holders. With Rocket Lab currently trading at roughly €61.50 — below the collar’s floor — the math becomes more dilutive the lower the stock goes. The deal is expected to close by mid-2027.
Strategically, the combination makes sense. Recurring, high-margin communications revenue and valuable spectrum rights would differentiate Rocket Lab from pure rocket builders. But the market is now being asked to price two unproven mega-bets simultaneously: Neutron’s technical debut and a large-scale corporate integration, all during a period when risk appetite for growth stories has visibly cooled.
What’s Next
The next concrete catalyst arrives August 10, when Rocket Lab reports second-quarter 2026 earnings after US market close. The report will offer the first detailed look at how the company is managing integration costs for its largest-ever acquisition alongside the final development phase of Neutron.
The average analyst price target of €100.56 implies roughly 63% upside from current levels, suggesting Wall Street still sees the fundamental growth story as intact. But the path to that target runs directly through the Neutron launch pad and a smooth Iridium close. Until Rocket Lab reaches the test stands that Beck himself has identified as the next true milestone, any recovery is likely to be choppy rather than linear. For now, the stock looks like a candidate for an oversold bounce — but not yet a name that has fully earned back the market’s trust.
Ad
Rocket Lab Stock: New Analysis - 24 July
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
